公开(公告)号：US09783527B2

公开(公告)日：2017-10-10

申请号：US14854433

申请日：2015-09-15

Applicant: AbbVie Inc.

Inventor： Jerome F. Daanen ,  David A. DeGoey ,  Jennifer M. Frost ,  John R. Koenig ,  Steve Latshaw ,  Mark Matulenko ,  Marc Scanio ,  Lei Shi ,  William H. Bunnelle

IPC: A61K31/497 ,  A61K31/4178 ,  A61K31/4985 ,  C07D403/04 ,  C07D403/14 ,  C07D487/14 ,  C07D491/08 ,  C07D413/14 ,  C07D405/14 ,  C07D417/14 ,  C07D401/14

CPC classification number: C07D403/14 ,  A61K31/4178 ,  A61K31/497 ,  A61K31/4985 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/14 ,  C07D491/08

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20160075692A1

公开(公告)日：2016-03-17

申请号：US14854433

申请日：2015-09-15

Applicant: AbbVie Inc.

Inventor： Jerome F. Daanen ,  David A. DeGoey ,  Jennifer M. Frost ,  John R. Koenig ,  Steve Latshaw ,  Mark Matulenko ,  Marc Scanio ,  Lei Shi ,  William H. Bunnelle

IPC: C07D403/14 ,  C07D401/14 ,  C07D405/14 ,  C07D491/08 ,  C07D413/14 ,  C07D403/04 ,  C07D417/14

CPC classification number: C07D403/14 ,  A61K31/4178 ,  A61K31/497 ,  A61K31/4985 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/14 ,  C07D491/08

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract translation: 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中A，R 1和R 2如说明书中所定义，可用于治疗由电压门控钠通道预防或改善的病症或障碍 ，例如Nav1.7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。